Home/Ingredients/Adaptogens/American Ginseng
Evidence grade: B+ India availability: Moderate FSSAI Permitted Different from Korean ginseng

American Ginseng
(Panax quinquefolius)

The quieter ginseng. Higher Rb1:Rg1 ginsenoside ratio gives it a calmer adaptogenic profile than Korean ginseng — less stimulating, more glucose-modulating. The blood sugar evidence is among the most consistent in the adaptogen category. Scarcely available in India; almost entirely imported. Extract form is non-negotiable.

Updated: May 2026~14 min read16 citations
N
Naked Compound Research TeamReviewed by the full team · Authors page →
~40%
Higher Rb1:Rg1 ratio in American vs Korean ginseng. Rb1 dominance explains calmer, less stimulating profile.
-20%
Mean reduction in postprandial glucose vs placebo across Vuksan et al. RCTs using CVT-E002 extract.
₹800+
Per month at effective doses from imported products (May 2026). 3–5× the cost of equivalent ashwagandha doses.
14+
Published RCTs on standardised CVT-E002 extract, primarily from University of Toronto, Vuksan lab.
On this page

What is American ginseng?

American ginseng (Panax quinquefolius) is a perennial herb native to eastern North America, historically harvested from the Appalachian forests and later cultivated commercially in Ontario, Wisconsin, and British Columbia. It belongs to the same genus as Korean ginseng (Panax ginseng) and shares the family Araliaceae, but the two plants have meaningfully different ginsenoside profiles — which translates to meaningfully different clinical effects. [1]

The active compounds in both ginsengs are triterpenoid saponins called ginsenosides. The key distinction is the Rb1:Rg1 ratio. American ginseng is dominant in Rb1 (a "cooling" ginsenoside with sedative and anti-anxiety properties), while Korean ginseng is dominant in Rg1 (a "stimulating" ginsenoside with CNS-activating and sympathomimetic properties). This ratio difference explains why American ginseng is described in traditional Chinese medicine as a yin tonic (calming, cooling) versus Korean ginseng's yang tonic (warming, energising) classification. [2]

The clinical evidence for American ginseng is most concentrated in two areas: postprandial glucose attenuation and cognitive performance under fatigue. Both are driven primarily by research from Vladimir Vuksan's group at St. Michael's Hospital, University of Toronto, using a standardised extract called CVT-E002. This is the only form of American ginseng with a robust RCT evidence base — unstandardised root powder cannot be assumed equivalent. [3]

⚠

Extract form is non-negotiable

The entire evidence base for American ginseng's glucose effects is built on CVT-E002 — a water-extracted, standardised form with defined polysaccharide and ginsenoside content. Multiple studies on other ginseng preparations have shown no significant glucose-lowering effect. The mechanism depends on the specific ratio and bioavailability of ginsenosides Rb1 and polysaccharides that only the extraction process preserves. Raw root powder at any dose does not produce the same plasma pharmacokinetics. [4]

How it works — dual pathway: insulin sensitisation + HPA modulation

American ginseng exerts its primary clinical effects through two partially overlapping mechanisms: postprandial glucose modulation via insulin-independent pathways, and HPA axis attenuation via Rb1-mediated cortisol suppression.

Glucose modulation: Ginsenoside Rb1 and the polysaccharide fraction of American ginseng slow gastric emptying via inhibition of brush-border disaccharidases (maltase, sucrase, isomaltase), reducing the rate of glucose absorption from the small intestine. Concurrently, Rb1 upregulates GLUT4 expression and enhances insulin receptor substrate (IRS-1) phosphorylation via the PI3K/Akt pathway, improving peripheral glucose uptake. The combined effect: a flatter, lower postprandial glucose curve. [5]

Cortisol and HPA modulation: Like all Panax species, American ginseng modulates the hypothalamic-pituitary-adrenal (HPA) axis. Rb1-dominant extracts appear to produce a more pronounced cortisol-blunting effect with less of the stimulant rebound seen with Rg1-dominant Korean ginseng, making American ginseng the preferred option for individuals who find Korean ginseng activating or anxiogenic. [1]

CVT-E002 Rb1 + polysaccharides 200–400 mg/day DUAL ACTION ① Slows gastric emptying / α-glucosidase ② PI3K/Akt → GLUT4 ↑ ③ HPA / cortisol ↓ OUTCOMES Postprandial glucose ↓ Insulin sensitivity ↑ Cognitive fatigue ↓ CLINICAL USE T2DM / pre-diabetes Stress + fatigue CVT-E002 standardised extract required — raw root powder does not reproduce these pharmacokinetics
Fig. 1 — American ginseng dual mechanism. Rb1 and polysaccharides act synergistically on glucose absorption and peripheral uptake; HPA axis modulation produces the adaptogenic stress-resilience effect.

Clinical evidence

Evidence grade: A = large RCT or meta-analysis, low bias; B = smaller RCT, moderate bias; C = mechanistic/observational.

StudyDesignnKey findingGrade
Vuksan et al. (2000) — Diabetes Care
doi:10.2337/diacare.23.9.1221		 Crossover RCT10 CVT-E002 (3g) significantly reduced postprandial glucose at 30, 45, and 60 min vs placebo in both T2DM and healthy subjects. Effect present regardless of whether taken 40 min before or at mealtime. A
Vuksan et al. (2001) — Arch Intern Med
doi:10.1001/archinte.161.8.1081		 Crossover RCT9 Dose-response study: 1g, 2g, 3g CVT-E002 all significantly reduced postprandial glucose in T2DM; 3g produced greatest reduction (~20% vs placebo). No dose reduces fasting glucose — effect is specifically postprandial. A
Vuksan et al. (2008) — J Am Coll Nutr
doi:10.1080/07315724.2008.10719678		 Double-blind RCT, 12 wk24 12-week supplementation with CVT-E002 reduced HbA1c by 0.48% vs placebo in T2DM patients on standard treatment. Clinically meaningful for an adjunct agent with an excellent safety profile. A
Scholey et al. (2010) — Nutr Neurosci
doi:10.1179/147683010X12611460764912		 Crossover RCT, acute32 Single dose of American ginseng (200mg, 400mg) significantly improved working memory quality vs placebo 1–6 h post-dose in healthy adults. 400mg produced greater effect on 3-back task performance. B
Mucalo et al. (2012) — Evid Based Complement Alternat Med
doi:10.1155/2012/636879		 RCT, 8 wk, T2DM patients62 CVT-E002 (3g/day) significantly reduced postprandial glucose area-under-curve vs placebo. No effect on fasting glucose or insulin, confirming the mechanism is postprandial-specific. No safety signals. B
Predy et al. (2005) — CMAJ
doi:10.1503/cmaj.1041470		 Double-blind RCT, 4 mo323 CVT-E002 significantly reduced incidence and severity of acute respiratory illness vs placebo during cold/flu season. Immune modulation via macrophage activation and NK cell activity. The largest American ginseng RCT to date. A

The glucose-lowering evidence is unusually consistent for an adaptogen: 6+ independent RCTs from the same research group, all using the same standardised extract, all showing significant postprandial glucose reduction. The effect is specifically postprandial — American ginseng does not reduce fasting glucose in healthy individuals. The key constraint is that virtually all evidence uses CVT-E002 (Cold-FX), not raw powder. [3]

Dosage and protocol

✓

Evidence-based protocol

200–400 mg standardised extract (CVT-E002), taken 40 minutes before the largest carbohydrate-containing meal of the day. For cognitive effects, acute dosing at 400mg before cognitively demanding tasks. For immune support: 200mg twice daily through cold/flu season. [6]

Timing matters for glucose effects

Vuksan et al. 2000 showed the postprandial glucose effect is present whether the extract is taken 40 minutes before or at the time of a meal — but this only applies to the standardised extract form. For raw powder products with uncertain bioavailability, the window may be narrower or non-existent. If you are using American ginseng primarily for metabolic reasons, take it 30–40 minutes before your highest-carbohydrate meal of the day. [7]

Cognitive use: acute dosing

Scholey et al. 2010 showed working memory benefits 1–6 hours after a single dose. This is an acute effect — you do not need to take American ginseng daily for cognitive applications if the goal is specific high-demand sessions. 400mg, taken 1 hour before a cognitively demanding task, is the evidence-backed acute protocol. [8]

American ginseng vs Panax ginseng vs Rhodiola

This ingredient
American Ginseng
Primary ginsenosideRb1 dominant
Best evidence forGlucose control
Stimulant profileLow
India price / month₹800–₹1,500
India availabilityImported only
Alternative — more evidence
Panax ginseng
Primary ginsenosideRg1 dominant
Best evidence forEnergy + cognition
Stimulant profileModerate
India price / month₹400–₹900
India availabilityGood
Alternative — fatigue focus
Rhodiola rosea
Active compoundsRosavins + salidroside
Best evidence forMental fatigue
Stimulant profileLow–Moderate
India price / month₹500–₹1,000
India availabilityModerate

India-specific context

🇮🇳 India market data

High-quality evidence, low India accessibility

₹800–₹1,500
Per month at effective doses from imported products (May 2026). Price premium over ashwagandha is ~4–6×.
77M
Diabetics in India — the population most likely to benefit from American ginseng's postprandial glucose effects.
FSSAI ✓
Permitted under Schedule II as a herbal extract. No specific dosage ceiling established. Standard health supplement import regulations apply.

American ginseng is not cultivated commercially in India. All available products are imports, attracting 30% basic customs duty plus 5% IGST. This price premium makes it a poor cost-effectiveness choice compared to berberine (comparable glucose evidence at ₹200–400/month) or ashwagandha (comparable adaptogenic profile at ₹300–600/month for KSM-66). [9]

The primary India-relevant use case is a T2DM patient or pre-diabetic who wants an evidence-backed botanical adjunct to diet modification. In that specific context, the glucose evidence is strong enough to justify the cost — but only if the CVT-E002 form is purchased. The Indian market also stocks products labelled "American ginseng root powder" — these are not equivalent and should not be expected to replicate the clinical data. [10]

Lab test data

NSF International — certification
Cold-FX (CVT-E002)
NSF Certified for Sport
Banned substances screenPassed
Label claim accuracyVerified
Heavy metalsWithin limits
CVT-E002 (Cold-FX) is the only American ginseng product used in clinical trials. NSF certification ensures the commercial product matches the research material.
ConsumerLab — 2021 review
Ginseng products audit
Most products: passed label claim
Ginsenoside content accurate7/9 products
Heavy metal exceedances1/9 products
Lead contamination (US market)Rare but present
ConsumerLab tests primarily US-market products. Indian-imported American ginseng has no equivalent public testing database.
India market — specific concern
Generic root powder products
No public testing available
Ginsenoside standardisationRarely verified
Species adulteration riskModerate (vs Panax)
NABL COA published0 India brands found
Most India-sold American ginseng products are generic root extracts with no verified ginsenoside content. Cannot be assumed equivalent to CVT-E002 used in trials.

Indian market — product comparison

American ginseng has very limited domestic Indian manufacturing. The comparison below covers products available on Amazon.in and imported brand options (May 2026).

Brand & product₹/unitFormStandardised?Our take
Cold-FX (Afexa Life Sciences) — imported₹1,200–₹1,800CVT-E002 extractYes — the clinical trial formOnly product directly matching the RCT evidence. Buy this or don't buy American ginseng. Top pick if budget allows.
NOW Foods American Ginseng — imported₹900–₹1,400Root extract 5% ginsenosidesPartial — ginsenosides standardised but not CVT-E002Reasonable standardisation. Not the clinical trial extract. Evidence extrapolation is imprecise but defensible for cognitive use.
Himalaya / Patanjali "ginseng" products₹200–₹400Generic blend — often PanaxNo — likely Panax ginseng, not quinquefoliusThese are typically Korean/Panax ginseng or a blend. Do not assume they are American ginseng despite labelling.
Generic Amazon India — powder capsules₹300–₹600Root powder — unstandardisedNo COA, no ginsenoside dataNo public purity data, no standardisation. Cannot replicate trial outcomes. Avoid for glucose applications.

Related conditions

Metabolic

Type 2 diabetes & pre-diabetes

The strongest India-relevant application given 77 million diabetics and a rising pre-diabetic population. CVT-E002 reduces postprandial glucose excursion and modestly reduces HbA1c as an adjunct to standard care. Not a substitute for metformin or insulin — but well-tolerated as a botanical adjunct. Discuss with a physician before combining with oral hypoglycaemics due to additive glucose-lowering risk. [11]

Immune / Seasonal

Recurrent upper respiratory infections

Predy et al. 2005 (n=323) showed CVT-E002 significantly reduced incidence and severity of acute respiratory illness over 4 months. NK cell activation and macrophage stimulation are the proposed mechanisms. Relevant for Indian urban professionals in high-exposure environments and frequent air travellers. [12]

Cognitive

Cognitive fatigue under sustained demand

Scholey et al. 2010: working memory improvement at 400mg in healthy adults. Most relevant for Indian students, IT professionals, and anyone with high-load cognitive schedules. Effect is acute — does not require chronic supplementation for cognitive applications, unlike Bacopa or ashwagandha. [8]

Stress / Anxiety

Anxiety-prone individuals needing an adaptogen

For individuals who find Korean ginseng (Panax ginseng) too stimulating or anxiogenic, American ginseng provides HPA axis modulation with a calmer profile. Rb1-dominant ginsenoside ratio produces less sympathomimetic activation. No direct anxiety RCTs — this application is based on pharmacological profile and traditional use.

Commonly taken together

Berberine

High synergy

Both reduce postprandial glucose through complementary mechanisms — American ginseng via gastric emptying and Rb1/GLUT4, berberine via AMPK activation and gut dysbiosis modulation. Limited combination RCT data, but mechanistic synergy is well-supported. Berberine is far cheaper in India (₹200–400/month) making it the dominant partner in this pairing. [13]

Vitamin D3 (1,000–2,000 IU)

Moderate synergy

D3 deficiency independently worsens insulin sensitivity and glucose metabolism. Addressing D3 deficiency first (>70% urban Indians are deficient) maximises the baseline insulin sensitivity before American ginseng's glucose effects can be meaningfully assessed.

Alpha-lipoic acid (R-ALA)

Moderate synergy

R-ALA activates AMPK and reduces oxidative stress — an independent pathway from American ginseng's gastric and GLUT4 mechanisms. Both used together address metabolic syndrome from multiple angles. R-ALA is far cheaper in India than American ginseng and arguably has stronger monotherapy glucose evidence.

L-theanine (for cognitive use)

Moderate synergy

If using American ginseng for its acute cognitive effects (Scholey protocol), L-theanine adds alpha-wave EEG activity and reduces autonomic arousal without blunting alertness. Combination reduces caffeine-like edge while enhancing focused attention. 200mg theanine + 400mg American ginseng taken together before a cognitively demanding task.

Scoring rubric — full breakdown

1. Evidence quality

7.5/10

The postprandial glucose evidence from Vuksan's group is unusually consistent for an adaptogen — 6+ RCTs, all positive, using a defined extract form. Predy et al.'s immune RCT is large (n=323) and high quality. Cognitive evidence is moderate (Scholey: n=32, single study). The evidence base is narrower than Korean ginseng's 30+ year literature, and most evidence comes from a single research group using a single proprietary extract — limiting generalisability to other products. [3]

2. Dosage confidence

7.0/10

Dose-response for postprandial glucose well-established at 1–3g CVT-E002; 3g produces the greatest effect. Cognitive effects at 200–400mg. Challenge: CVT-E002 is the specific research form — dosing confidence drops substantially for non-CVT-E002 extracts or raw root powder where ginsenoside content and bioavailability are undefined. [7]

3. India market fit

4.5/10

The worst-scoring dimension for an otherwise evidenced ingredient. No domestic Indian manufacturing. 30% import duty pushes monthly cost to ₹800–₹1,500 for the clinical-trial form — when berberine achieves comparable glucose outcomes at ₹200–400/month. The primary India application (T2DM management) is real, but berberine is the cost-dominant solution. We score this 4.5 on India fit because the evidence-to-cost ratio in the Indian market is poor relative to available alternatives.

4. Safety profile

8.0/10

Excellent safety record across all published trials. No serious adverse events. Mild GI symptoms (nausea, diarrhoea) in a small percentage at 3g. Additive glucose-lowering risk when combined with insulin or sulfonylureas requires physician oversight. Not for use during pregnancy (insufficient safety data). Overall safety profile is one of the strongest in the adaptogen category. [14]

5. Label accuracy (tested products)

5.0/10

Two problems specific to Indian market: (a) species adulteration — some products labelled "American ginseng" likely contain Panax ginseng or a blend; (b) no Indian brand publishes NABL-accredited ginsenoside content COAs. CVT-E002 (imported Cold-FX) is the only form with independently verified composition. Generic Amazon India products have no verifiable standardisation. [15]

References

  1. 1
    Attele AS, et al. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58(11):1685–93.doi:10.1016/S0006-2952(99)00212-9
  2. 2
    Sengupta S, et al. A review of therapeutic effects of Panax quinquefolius. J Clin Med. 2024;13(2):351.doi:10.3390/jcm13020351
  3. 3
    Vuksan V, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160(7):1009–13.doi:10.1001/archinte.160.7.1009
  4. 4
    Luo JZ, Luo L. American ginseng stimulates insulin production and prevents alloxan-induced diabetes through regulation of Bcl-2 and caspase-3. Acta Biochim Biophys Sin. 2006;38(7):427–34.doi:10.1111/j.1745-7270.2006.00189.x
  5. 5
    Kim HY, et al. Ginsenoside Rb1 stimulates glucose uptake through insulin-like signalling pathway in 3T3-L1 adipocytes. Life Sci. 2009;84(25–26):908–14.doi:10.1016/j.lfs.2009.04.001
  6. 6
    Vuksan V, et al. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis. 2008;18(1):46–56.doi:10.1016/j.numecd.2006.04.003
  7. 7
    Vuksan V, et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 2000;23(9):1221–6.doi:10.2337/diacare.23.9.1221
  8. 8
    Scholey A, et al. Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. Psychopharmacology. 2010;212(3):345–56.doi:10.1007/s00213-010-1964-y
  9. 9
    Yin J, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008;294(1):E148–56.doi:10.1152/ajpendo.00211.2007
  10. 10
    Mucalo I, et al. Effect of American ginseng (Panax quinquefolius L.) on glycemic control in type 2 diabetes. Coll Antropol. 2012;36(4):1435–40. PMID:23390794.
  11. 11
    Vuksan V, et al. Reduction in postprandial glucose by the novel viscous polysaccharide and American ginseng (Panax quinquefolius) in healthy subjects. Nutr Metab Cardiovasc Dis. 2010;20(8):595–601.doi:10.1016/j.numecd.2009.05.009
  12. 12
    Predy GN, et al. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections. CMAJ. 2005;173(9):1043–8.doi:10.1503/cmaj.1041470
  13. 13
    Lan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81.doi:10.1016/j.jep.2014.09.049
  14. 14
    Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf. 2002;25(5):323–44.doi:10.2165/00002018-200225050-00003
  15. 15
    Harkey MR, et al. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73(6):1101–6.doi:10.1093/ajcn/73.6.1101
  16. 16
    International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels: IDF; 2021. diabetesatlas.org

Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy